• Binding commitments for A$75 million two-tranche placement
• Funds to support accelerated US commercialisation and expansion of Salix® platform
• Launch of up to A$5 million share purchase plan (SPP) for eligible shareholders

Artrya Limited (ASX: AYA), a medical technology company commercialising its Salix® AI-powered cloud platform, has received binding commitments for a A$75 million two-tranche placement at A$2.05 per share. The placement proceeds will be used to support accelerated US commercialisation and expansion, customer success and support, market access and reimbursement enablement, product development, research & development, and working capital, including the flagship SAPPHIRE plaque study. The company has also launched a A$5 million share purchase plan (SPP) at the same price as the placement, open to eligible shareholders on the record date of 8 September 2025. The capital raising will enable Artrya to accelerate the commercial roll-out of its Salix® software in the US, expand adoption across major US hospital groups, and advance the SAPPHIRE study to generate clinical evidence for assessing and treating patients at risk of coronary artery disease.

The funds raised will be used to accelerate the commercial roll-out of Salix® software in the US, expand adoption across major US hospital groups, and advance the SAPPHIRE study to generate clinical evidence for assessing and treating patients at risk of coronary artery disease.

The success of the capital raising affirms market recognition and Artrya's belief in the importance of the Salix® software in addressing the large and growing global health challenge of coronary artery disease. The company looks forward to the support of new and existing shareholders as it advances through this exciting next phase.